An activated excretion-retarded tumor imaging strategy towards metabolic organs

Hou, Da‐Yong; Wang, Man‐Di; Hu, Xiaofang; Wang, Zhijia; Zhang, Ni-Yuan; Lv, Gan-Tian; Wang, Jiaqi; Wu, Xiu-Hai; Wang, Lu; Wang, Hao; Xu, Wanhai

doi:10.1016/j.bioactmat.2021.12.003

Cited by 19 publications

(11 citation statements)

References 38 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the subsequent work, they further demonstrated that the activated excretion-retarded tumor imaging (AERTI) was successfully accumulated at the tumor sites in the RCC xenograft models with a tumor retention time up to 72 h (Fig. 4 ) [ 89 ]. Besides, the lymphatic drainage may not follow the known pattern.…”

Section: Treatment Of Renal Cell Carcinoma Using Nanomedicinementioning

confidence: 99%

See 1 more Smart Citation

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond

Wang

Gai

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

The kidney is a vital organ responsible for maintaining homeostasis in the human body. However, renal cell carcinoma (RCC) is a common malignancy of the urinary system and represents a serious threat to human health. Although the overall survival of RCC has improved substantially with the development of cancer diagnosis and management, there are various reasons for treatment failure. Firstly, without any readily available biomarkers, timely diagnosis has been greatly hampered. Secondly, the imaging appearance also varies greatly, and its early detection often remains difficult. Thirdly, chemotherapy has been validated as unavailable for treating renal cancer in the clinic due to its intrinsic drug resistance. Concomitant with the progress of nanotechnological methods in pharmaceuticals, the management of kidney cancer has undergone a transformation in the recent decade. Nanotechnology has shown many advantages over widely used traditional methods, leading to broad biomedical applications ranging from drug delivery, prevention, diagnosis to treatment. This review focuses on nanotechnologies in RCC management and further discusses their biomedical translation with the aim of identifying the most promising nanomedicines for clinical needs. As our understanding of nanotechnologies continues to grow, more opportunities to improve the management of renal cancer are expected to emerge.

show abstract

Section: Treatment Of Renal Cell Carcinoma Using Nanomedicinementioning

confidence: 99%

“…The tumor boundary identified by naked eyes, fluorescence imaging, H&E and fluorescence microscopy imaging results. Figure adapted from Da-Yong Hou et al [ 89 ] …”

Section: Treatment Of Renal Cell Carcinoma Using Nanomedicinementioning

confidence: 99%

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond

Wang

Gai

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…It is ideal to deliver embolic agents to the target vessel to block the blood and nutrient supply and is thus considered a promising mini-invasive technique. Real-time intraoperative guidance is crucial during surgery operation for complete and safe tumor resection. − Imaging, as one of the attractive topics in modern medical application, has exhibited great potential in the early diagnosis and effective treatment of most diseases including malignant tumors, inflammation, and vascular diseases. − It can be roundly used in diagnosis, target localization, surgical navigation, and assessment responses to post-therapy. Due to the limitations of imaging equipment, imaging probes are generally used to obtain accurate molecular data .…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Interventional Fluorescence Imaging: Toward the Precise Visualization of Transarterial Mini-Invasive Delivery Systems

et al. 2023

View full text Add to dashboard Cite

Interventional fluorescence imaging has gradually developed into a promising imaging strategy for the diagnosis of diseases in clinic. This strategy could benefit interventional targeted treatment because of the clear display of microstructures at the margins and boundaries. There are some stranded crucial issues in clinical application: (i) fast clearance of fluorescence probes; (ii) light instability and photobleaching; and (iii) residual and microsatellite lesions. The development of superstable homogeneous intermixed formulation technology (SHIFT) can solve the aforementioned clinical problems for precision hepatectomy. Interventional fluorescence imaging based on SHIFT-prepared product has some advantages such as (i) strong stability, (ii) greatly extending imageable time window, and (iii) precisely visualizing microsatellite lesions. In this Account, we overview our current progress in interventional fluorescence imaging based on SHIFT method for surgical resection following long-lasting embolization conversion. To greatly realize interventional fluorescence imaging, we summarize clinical and preclinical application of interventional fluorescence imaging in a transarterial delivery system. Indeed, compared with conventional fluorescence imaging, interventional fluorescence imaging possesses non-negligible strengths on improved intensity in target location and step-down systemic toxicity. Unfortunately, a challenging issue is that immobile fluorescence performance is difficult to maintain after long-time embolization, resulting in a failed hepatectomy. On this basis, associated with our previous research, SHIFT was proposed and developed. Thus, we detailedly introduce and account the development and preponderance of SHIFT on interventional fluorescence imaging. Predictably, after lengthy embolization, its lightful fluorescence was still observable in tumor targets of a clinical trial. To regulate the fluorescence rendering of microsatellite lesion, SHIFT combining with pure nanoprobes (nanoICG) occurs, namely SHIFT nanoICG, and we dwell on its performance in transarterial invasive surgical navigation and its clinical application under interventional fluorescence imaging compared with conventional indocyanine green (ICG) formulations. Amazingly, the SHIFT nanoICG brings us an extraordinary imaging consequence for deep-seated tumor tissues and imperceptible microsatellite lesions. Finally, we offer perspectives on the future tendency of interventional imaging-guided SHIFT products in clinical translation such as chemoembolization, radioembolization, and immunotherapy. Actually, these directions have been underway for some time, and even relative products are already applied for clinical trials, exhibiting effective therapeutic outcomes. Our green high-performance SHIFT products are concentrated on meeting clinical needs and solving clinical problems, breaking through the cure limitations of patients with advanced diseases. Thus, the discovery offers insight into the development and superiority of SHIFT product...

show abstract

“…1A ). The modular molecular design included (i) mannose, as a TAM recognition and modulation molecule ( 28 ); (ii) LGASWHRPDK, as a tumor recognition motif, which could specifically bind CXCR4 ( 29 ); (iii) PLG ↓ YLG, as an enzyme-responsive peptide linker, which could be specifically cleaved by matrix metalloproteinase 2 (MMP-2) ( 30 ); and (iv) KLVFFAECG, as a self-assembly motif ( 31 , 32 ). In the TME, bsGP repolarized M2-like TAMs surrounding tumor cells to the M1 phenotype and then increased the recruitment of CD8 + T cells, which were spatially redirected to tumor cells, resulting from remodeling of the immunosuppressive TME.…”

Section: Introductionmentioning

confidence: 99%

A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence

Hou

Yang

et al. 2023

Sci. Adv.

Self Cite

View full text Add to dashboard Cite

Up to 75% of bladder cancer patients suffer from recurrence due to postoperative tumor implantation. However, clinically used Bacillus Calmette-Guerin (BCG) treatment failed to inhibit the recurrence. Here, we report a bispecific glycopeptide (bsGP) that simultaneously targets CD206 on tumor-associated macrophages (TAMs) and CXCR4 on tumor cells. bsGP repolarizes protumoral M2-like TAMs to antitumor M1-like that mediated cytotoxicity and T cell recruitment. Meanwhile, bsGP is cleaved by the MMP-2 enzyme to form nanostructure for the long-term inhibition of CXCR4 downstream signaling, resulting in reduced tumor metastasis and promoted T cell infiltration. In orthotopic bladder tumor models, bsGP reduced the postoperative recurrence rate to 22%. In parallel, the recurrence rates of 89 and 78% were treated by doxycycline and BCG used in clinic, respectively. Mechanistic studies reveal that bsGP reduces the matrix microenvironment barrier, increasing the spatially redirected CD8 + T cells to tumor cells. We envision that bis-targeting CD206 and CXCR4 may pave the way to inhibit tumor metastasis and recurrence.

show abstract

An activated excretion-retarded tumor imaging strategy towards metabolic organs

Cited by 19 publications

References 38 publications

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond

Nanomedicine for renal cell carcinoma: imaging, treatment and beyond

Recent Advances in Interventional Fluorescence Imaging: Toward the Precise Visualization of Transarterial Mini-Invasive Delivery Systems

A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence

Contact Info

Product

Resources

About